Journal Article Review Epublish 1 citation
PubMed: 40004236 DOI: 10.3390/ijms26041773
Microbiota and Inflammatory Markers: A Review of Their Interplay, Clinical Implications, and Metabolic Disorders.
Int J Mol Sci 26(4)
Authors: Emiliano Peña-Durán, Jesús Jonathan García-Galindo, Luis Daniel López-Murillo, Alfredo Huerta-Huerta, Luis Ricardo Balleza-Alejandri, Alberto Beltrán-Ramírez, Elsa Janneth Anaya-Ambriz, Daniel Osmar Suárez-Rico
Affiliations
- Licenciatura en Médico Cirujano y Partero, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara 44340, Mexico.
- Departamento de Fisiología, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Calle Sierra Mojada 950, Independencia Oriente, Guadalajara 44340, Mexico.
- Departamento Académico Aparatos y Sistemas II, Decanato de Ciencias de la Salud, Universidad Autónoma de Guadalajara, Zapopan 44670, Mexico.
- Departamento Académico Aparatos y Sistemas I, Decanato de Ciencias de la Salud, Universidad Autónoma de Guadalajara, Zapopan 44670, Mexico.
- Hospital Medica de la Ciudad, Santa Catalina, Calle. Pablo Valdez 719, La Perla, Guadalajara 44360, Mexico.
- Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
- Departamento de Ciencias de la Salud, Centro Universitario de los Valles, Universidad de Guadalajara, Ameca 46708, Mexico.
- Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías (CUCEI), Universidad de Guadalajara, Guadalajara 44430, Mexico.
Abstract
The human microbiota, a complex ecosystem of microorganisms, plays a pivotal role in regulating host immunity and metabolism. This review investigates the interplay between microbiota and inflammatory markers, emphasizing their impact on metabolic and autoimmune disorders. Key inflammatory biomarkers, such as C-reactive protein (CRP), interleukin-6 (IL-6), lipopolysaccharides (LPS), zonulin (ZO-1), and netrin-1 (Ntn1), are discussed in the context of intestinal barrier integrity and chronic inflammation. Dysbiosis, characterized by alterations in microbial composition and function, directly modulates the levels and activity of these biomarkers, exacerbating inflammatory responses and compromising epithelial barriers. The disruption of microbiota is further correlated with increased intestinal permeability and chronic inflammation, serving as a precursor to conditions like type 2 diabetes (T2D), obesity, and non-alcoholic fatty liver disease. Additionally, this review therapeutic strategies, including probiotics and prebiotics, designed to restore microbial balance, mitigate inflammation, and enhance metabolic homeostasis. Emerging evidence positions microbiota-targeted interventions as critical components in the advancement of precision medicine, offering promising avenues for diagnosing and treating inflammatory and metabolic disorders.
MeSH
Dysbiosis, Chronic Disease, Insulin Resistance, Interleukin-6, Biomarkers, Probiotics, Microbiota
Cited by
- aggravates inflammatory response in mice oral mucositis through regulating Th17/Treg imbalance. Front Cell Infect Microbiol, 2025
- Exercise orchestrates systemic metabolic and neuroimmune homeostasis via the brain-muscle-liver axis to slow down aging and neurodegeneration: a narrative review. Eur J Med Res, 2025
- Correlations between serum cytokines and gut microbiota in patients with Graves' disease: A case-control study. Medicine (Baltimore), 2025
- Mechanistic Links Between Gut Dysbiosis, Insulin Resistance, and Autism Spectrum Disorder. Int J Mol Sci, 2025
- Association Between Oral Microbiota Dysbiosis and the Risk of Dementia: A Systematic Review. Dent J (Basel), 2025
- The prognostic and diagnostic significance of inflammatory markers TNF-α, IL-6, and IFN-γ in evaluating disease severity in diabetic foot infection. Front Cell Infect Microbiol, 2025